Skip to main content
Equibles
CAPR logo

CAPR · Capricor Therapeutics, Inc.

Track CAPR — free

Use CAPR with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research CAPR.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$7.92 -0.18 (-2.22%)
Russell 2000 member Rebalance outlook locked
Market Cap
$498.25M
Shares
58.14M
Volume · Oct 8 260.48K Avg daily vol (3M) 6.87M

Price & Indicators

Drag to pan · scroll to zoom
Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$8.10 Open$7.59 Day$7.46–8.27 52W close$3.85–35.34 Avg vol 30d4.5M Short int19.7M · 33.9% float · 5.9d Short vol44% Last earningsAug 13, 2026 DataJan 2020–Oct 2026 Filing10-Q · Aug 14

Up next

Next earnings call
Nov 13, 2026 Est · unconfirmed · in 5 wks
Latest filing: 10-Q
filed Aug 14, 2026
Q2 2026 earnings call transcript
call held Aug 13, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$22.27M
Trailing 12 months
Net income (TTM)
−$129.42M
Trailing 12 months
Revenue growth YoY
-7.9%
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-23.1%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+26.7%
Year over year · more shares
Price change (1Y)
+8.0%
Trailing year
Short interest
33.9%
Latest settlement · 5.9 days to cover
View all 115 metrics

AI Brief

Q2 FY26 earnings call · Aug 13, 2026
Q2 FY26

TL;DR. Capricor reported Q2 with an adverse FDA Advisory Committee vote (3-9) against its cardiomyopathy indication, but plans a BLA amendment focused on the HOPE-3 upper limb primary endpoint; net loss widened to $40.7M on $42.9M of operating expenses, with $237.9M in cash.

Bullish
  • + Company plans a BLA amendment targeting the HOPE-3 upper limb primary endpoint, with FDA willing to review and extend the PDUFA date
  • + HOPE-3 primary endpoint remained statistically significant (PUL 2.0 mean difference 4.55% favoring deramiocel, p=0.029)
  • + Full HOPE-3 Phase 3 dataset published in The Lancet following extensive peer review
  • + Cash position of approximately $237.9M expected to fund operations for at least the next twelve months
  • + In-house San Diego GMP manufacturing facility is operational and positioned to support initial commercial launch if approved
Bearish
  • − FDA Advisory Committee voted 3-9 against deramiocel on the cardiomyopathy effectiveness question
  • − Net loss widened to approximately $40.7M ($0.70/share) from approximately $25.9M ($0.57/share) year-over-year
  • − Total operating expenses rose to approximately $42.9M from approximately $27.7M year-over-year
  • − No revenue recognized for Q2 2026 or 2025, and pipeline programs beyond deramiocel are on hold pending regulatory clarity
  • − FDA BIMO inspection resulted in a Form 483 with one observation, with feedback still pending
  • − Statistical model revision weakened the LVEF key secondary endpoint to p=0.09 (1.8pp) from the prior reported p=0.04 (2.4pp)

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Equibles Rating

blended score · not investment advice
Overall
Strong Sell
SellHoldBuy
Technical Sell Momentum Very Weak Sentiment Bullish Fundamentals Poor Quant / Vol Very High
Market backdrop VIX 15.1 · calm Equity put/call 0.63
Technical
price trend
Sell
50 / 200-day cross No cross
Price vs 200-day avg −64%
below
Price vs 50-day avg +7%
above
RSI (14) 44
neutral
MACD trend Negative
52-week position 13%
near low
Momentum
relative strength
Very Weak
1-month return −6%
trailing
6-month return −77%
trailing
YTD return −72%
this year
Relative strength −88%
vs S&P · 6-mo
Sentiment
smart money
Bullish
Trend (MA cross) No cross
50d $8 › 200d $23 — 200d above 50d
Institutional flow Accumulating
2 of 176 funds reported for Sep 30 · net +94 sh shares · +1 new
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
33.85% of float · ▼ -11.3% MoM · 5.9 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
176 holders — near 3-yr high, broad support
Squeeze score 72
high risk · 0–100
Fundamentals
Poor
Revenue growth −100%
Y/Y
EPS growth −97%
Y/Y
Free cash flow $-72.7M
Quant / Vol
risk profile
Very High
Volatility 394%
annualized · 1-yr
Max drawdown −89%
past year
ATR 10.8%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Sell
3 · 2 · 1
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−64% Bearish
Price vs 50-day avg
+7% Bullish
RSI (14)
44 Neutral
MACD trend
Negative Bearish
52-week position
13% Bearish
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross) No cross
50d $8 › 200d $23 — 200d above 50d
Institutional flow Accumulating
2 of 176 funds reported for Sep 30 · net +94 sh shares · +1 new
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
33.85% of float · ▼ -11.3% MoM · 5.9 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
176 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $4 Now $8 · 13% Range high $35
vs 200-day avg -64% vs 50-day avg +7%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
CAPR
Capricor Therapeutics, Inc.
this stock
$498.25M -71.9% -100.0% — 33.9%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $128.16B +11.5% +46.2% 29.5 1.9%
MRNA
Moderna, Inc.
 $78.44B +566.3% +4.3% — 8.2%
REGN
Regeneron Pharmaceuticals, Inc.
 $76.40B -3.9% +20.8% 18.4 2.5%
CSLLY
Csl Ltd
 $61.25B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
177
% held
79.0%
Reported
2 of 176
Top holder
BlackRock, Inc.
Held Float
View
Held by Funds
Fund positions
139
View
Short & Settlement
Short Interest Falling
Shares short
19.7M
Days to cover
5.9d
Change
-2.5M sh
View
Short Volume
Short vol %
44%
As of
Oct 7, 2026
Short Total
View
Fails to Deliver
FTD shares
253
Value
$2.2K
As of
Sep 10, 2026
View
Off-Exchange
Off-exchange %
48.4%
Week of
Aug 31, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$0
Net income (FY)
$-105.0M
EPS diluted
$-2.26
View
Filings
SEC Filings
Latest
8-K
Filed
Aug 24, 2026
This year
17
View
Proposed Sales
Value
$2.4M
Shares
88.8K
Filed
May 19, 2026
View
Earnings & Events
Webcasts
Last webcast
Aug 13, 2026
View

Performance

5D 20D 120D MTD YTD
CAPR -14.5% -6.3% -76.9% -14.5% -71.9%
SPY +1.9% +1.9% +10.8% +1.9% +14.0%
vs SPY -16.4% -8.2% -87.7% -16.4% -85.9%
Key facts CIK 1133869 CUSIP 14070B309 13F (30d) 6 filings 6 filers Visit website Investor relations